Medulloblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
- $ 2000
- April 2024
- 143 pages
It is under development for the treatment of adenocarcinoma of the gastroesophageal junction and newly diagnosed medullablastoma. [...] It was under development for the treatment of acute lymphocytic leukemia, acute myelocytic leukemia, child- pugh A cirrhosis, pancreatic adenocarcinoma, platinum-resistant or refractory or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma, myelofibrosis, post essential thrombocythemia myelofibrosis, post polycythemia vera myelofibrosis, adenocarcinoma of esophagus or gastroesophageal junction, extensive stage small-cell lung cancer, advanced or metastatic hepatocellular carcinoma, relapsed or refractory multiple myeloma, Gorlin syndrome, sporadic superficial nodular skin basal cell carcinomas, medulloblastoma, solid tumor, hematologic malignancies and chronic myelocytic leukemia, hedgehog pathway-mutated myelodysplastic syndrome, recurrent glioblastoma multiforme, estrogen receptor negative and HER2 negative breast cancer, metastatic colorectal cancer, castration-resistant prostate cancer, steroid-refractory chronic graft versus host disease (GVHD) after allogeneic HSCT.